Covid vaccine, Novavax, delay rumours, weighing on sentiment

There is a rumour that the Novavax vaccine is delayed, which has seen the stock drop some 6% in recent trade.

Novavax, Inc. (Nasdaq: NVAX), is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, including NVX-CoV2373, the Company’s COVID-19 vaccine.

The news of the delay is problematic for risk-sensitive asset classes as financial markets bare the latest alarming surges of the course throughout Europe and the US.

Both European and US stocks have had a terrible start to the week on the back of the second wave headlines of the weekend and the latest update from data compiled by Johns Hopkins University:

Confirmed global cases of COVID-19 has soared to 43 million according to the latest The death toll has also climbed to 1.15 million.

The latest surge has forced many European countries to tighten restrictions on activity.

The US infections have also skyrocketed past the prior peak of July, forcing El Paso in Texas to ask citizens to stay at home for the next two weeks.

The negative sentiment has fed through to Wall Street setting the Dow for its worst day in more than seven weeks.

At the time of writing, the major indexes are down Dow 2.29%, S&P 1.89%, Nasdaq 1.58%, albeit off their worst levels of the day, so far.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.